DM1-SMe
Based on 1 Customer Validation
DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is the microtubule inhibitor and can be used as the ADC cytotoxin.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.08%
- CAS 番号: 138148-68-2
- 分子式: C36H50ClN3O10S2
- 分子量:784.38
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
ADC Payloads アイソフォーム固有の製品をすべて表示
More
生物活性
|
Maytansinoids |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:PPTP solid tumor xenograft mouse model[1].
-
Dosage:15 mg/kg in form of IMGN901
-
Administration:iv, three times a week for 6 weeks
-
Result:Inhibited tumor growth.
化学情報
-
CAS 番号 138148-68-2
-
性状 Solid
-
分子量 784.38
-
分子式 C36H50ClN3O10S2
-
Color Off-white to light yellow
-
SMILES
C[C@]12[C@@]([C@@H]([C@]3([H])C[C@]([C@@H](/C=C/C=C(CC4=CC(N(C(C[C@@H]2OC([C@H](C)N(C)C(CCSSC)=O)=O)=O)C)=C(C(OC)=C4)Cl)\C)OC)(NC(O3)=O)O)C)([H])O1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶剤 & 溶解度
DMSO : 100 mg/mL (127.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (279 KB)
-
SDS (483 KB)
- English - EN (483 KB)
- Français - FR (483 KB)
- Deutsch - DE (483 KB)
- Norwegian - NO (483 KB)
- Español - ES (483 KB)
- Swedish - SV (483 KB)
- Italian - IT (483 KB)
- Korean - KR (483 KB)
- Portuguese - PT (483 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Wood AC, et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(11):1860-1867. [Content Brief]
[2]. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2749 mL | 6.3745 mL | 12.7489 mL | 31.8723 mL |
| 5 mM | 0.2550 mL | 1.2749 mL | 2.5498 mL | 6.3745 mL | |
| 10 mM | 0.1275 mL | 0.6374 mL | 1.2749 mL | 3.1872 mL | |
| 15 mM | 0.0850 mL | 0.4250 mL | 0.8499 mL | 2.1248 mL | |
| 20 mM | 0.0637 mL | 0.3187 mL | 0.6374 mL | 1.5936 mL | |
| 25 mM | 0.0510 mL | 0.2550 mL | 0.5100 mL | 1.2749 mL | |
| 30 mM | 0.0425 mL | 0.2125 mL | 0.4250 mL | 1.0624 mL | |
| 40 mM | 0.0319 mL | 0.1594 mL | 0.3187 mL | 0.7968 mL | |
| 50 mM | 0.0255 mL | 0.1275 mL | 0.2550 mL | 0.6374 mL | |
| 60 mM | 0.0212 mL | 0.1062 mL | 0.2125 mL | 0.5312 mL | |
| 80 mM | 0.0159 mL | 0.0797 mL | 0.1594 mL | 0.3984 mL | |
| 100 mM | 0.0127 mL | 0.0637 mL | 0.1275 mL | 0.3187 mL |